Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients

This study examines the relationship between a test called HRD (homologous recombination deficiency) score and how well PARP inhibitors — a type of targeted therapy — work in women with advanced ovarian, fallopian tube, or peritoneal cancer. Researchers want to understand which patients benefit most from this treatment. **You may be eligible if...** - You are a woman aged 18 or older - You have advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer diagnosed after January 2015 - You are receiving or have received PARP inhibitor maintenance therapy after chemotherapy - You are in good health with stable CA125 levels (ECOG 0–2) - You have adequate heart, liver, and kidney function **You may NOT be eligible if...** - You have had another cancer within the last 5 years - You are unable to understand or cooperate with study requirements Talk to your doctor to see if this trial is right for you.